In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0101 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Hyeon-Ju Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA (H.A., A.D.). Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, Texas, USA (H.A., A.D.).
Zitieren
APA
Ali, H. J., & Deswal, A. (2023). In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. Annals of Internal Medicine. https://doi.org/10.7326/j23-0101
Vancouver
Ali HJ, Deswal A. In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. Annals of Internal Medicine. 2023. doi:10.7326/j23-0101
BibTeX
@article{Ali2023,
author = {Ali, Hyeon-Ju and Deswal, Anita},
title = {In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0101}
}
EUVIMED